Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.

Huang, Liang; Shimoji, Mika; Wang, Juan; Shah, Salim; Kamila, Sukanta; Biehl, Edward R; Lim, Seung; Chang, Allison; Maguire-Zeiss, Kathleen A; Su, Xiaomin; Federoff, Howard J

Huang, Liang; Shimoji, Mika; Wang, Juan; Shah, Salim; Kamila, Sukanta; Biehl, Edward R; Lim, Seung; Chang, Allison; Maguire-Zeiss, Kathleen A; Su, Xiaomin; Federoff, Howard J.

Affiliation

Huang L; Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA.

Neurotherapeutics ; 10(4): 840-51, 2013 Oct.

Article in En | MEDLINE | ID: mdl-23963789

Subject(s)

Cell Line; Parkinson Disease/therapy; Protein Serine-Threonine Kinases/genetics; Cell Survival/genetics; Dopaminergic Neurons/metabolism; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Parkinson Disease/genetics; Parkinson Disease/metabolism; Phosphorylation; Protein Serine-Threonine Kinases/metabolism

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Cell Line / Protein Serine-Threonine Kinases Limits: Humans Language: En Journal: Neurotherapeutics Journal subject: NEUROLOGIA Year: 2013 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google